Skip to main content
SpringerLink
Log in
Book cover

International Manual of Oncology Practice pp 241–269Cite as

Breast Cancer

  • Chapter
  • First Online:

  • 789 Accesses

Abstract

Breast cancer is not a single disease. It is highly heterogeneous in its molecular biology and natural evolution, impacting treatment response and prognosis. It is one of the most prevalent cancers worldwide with high impact on individual, social and economic levels. Nowadays, breast cancer treatment demands a multidisciplinary approach and the involvement of informed patients. Personalized breast cancer care should mean both considering the prognostic and predictive biomarkers of a single tumor and considering an individual patient’s preferences.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

AI:

Aromatase inhibitor

BC:

breast cancer

CDK4/6:

cyclin-dependent kinases 4/6

cD1:

cyclin D1

CT:

computed tomography

ER:

estrogen receptor

ET:

endocrine therapy

GnRH:

gonadotropin-releasing hormone

HER2:

human epidermal growth factor receptor 2

LN:

lymph node

mAb:

monoclonal antibody

MBC:

metastatic breast cancer

MRI:

magnetic resonance imaging

NST:

no special type

OFS:

ovarian function suppression

OS:

overall survival

PARP:

poly-adenosine diphosphate-ribose polymerase inhibitor

pCR:

pathological complete response

PET-CT:

positron emission computed tomography

PFS:

progression-free survival

PR:

progesterone receptor

SERD:

selective estrogen receptor degrader

SERM:

selective estrogen receptor modulator

SLN:

sentinel lymph node

SLNB:

sentinel lymph node biopsy

TILs:

tumor-infiltrating lymphocytes

TNM:

tumor node metastasis

References

  1. International Agency for Research on Cancer (2012) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012

    Google Scholar 

  2. American Cancer Society (2015) Global cancer facts & figures, 3rd edn. American Cancer Society, Atlanta

    Google Scholar 

  3. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S et al (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010

    Article  PubMed  Google Scholar 

  4. Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y et al (2017) Risk factors and preventions of breast Cancer. Int J Biol Sci 13(11):1387–1397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Prev Biomarkers 15(6):1159–1169

    Article  Google Scholar 

  6. Collaborators MWS (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427

    Article  CAS  Google Scholar 

  7. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15):1684–1692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cancer CGoHFiB (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713–1727

    Article  Google Scholar 

  9. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL et al (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372(23):2243–2257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A (2010) Male breast cancer. Crit Rev Oncol Hematol 73(2):141–155

    Article  PubMed  Google Scholar 

  11. Screening IUPoBC (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380(9855):1778–1786

    Article  Google Scholar 

  12. Miglioretti DL, Lange J, Van Den Broek JJ, Lee CI, Van Ravesteyn NT, Ritley D et al (2016) Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study. Ann Intern Med 164(4):205–214

    Article  PubMed  PubMed Central  Google Scholar 

  13. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E et al (2015) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(suppl_5):v8–v30

    Article  PubMed  Google Scholar 

  14. Network NCC (2017) NCCN clinical practice guidelines in oncology (NCCN guidelines®) breast cancer screening and diagnosis version 1.2017

    Google Scholar 

  15. Peccatori F, Azim H Jr, Orecchia R, Hoekstra H, Pavlidis N, Kesic V et al (2013) Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(suppl_6):vi160–vvi70

    PubMed  Google Scholar 

  16. Cardoso F, Kataja V, Tjan-Heijnen V (2017) Essentials for clinicians on breast cancer. ESMO Press, Lisbon

    Google Scholar 

  17. Tan AR (2016) Cutaneous manifestations of breast cancer. Semin Oncol 43(3):331–334

    Article  PubMed  Google Scholar 

  18. Dubar S, Boukrid M, de Joliniere JB, Guillou L, Vo QD, Major A et al (2017) Paget’s breast disease: a case report and review of the literature. Fron Surg 4:51

    Article  CAS  Google Scholar 

  19. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ et al (2017) Breast cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290–303

    Article  PubMed  Google Scholar 

  20. Gospodarowicz MK, Brierley JD, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons, Oxford

    Google Scholar 

  21. Glück S (2017) Consequences of the convergence of multiple alternate pathways on the estrogen receptor in the treatment of metastatic breast cancer. Clin Breast Cancer 17(2):79–90

    Article  CAS  PubMed  Google Scholar 

  22. de Paula Costa Monteiro I, Madureira P, De Vasconscelos A, Humberto Pozza D, Andrade de Mello R (2015) Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. Pharmacogenomics 16(3):257–271

    Article  CAS  Google Scholar 

  23. Mukohara T (2015) PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer: Targets Ther 7:111

    CAS  Google Scholar 

  24. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137

    Article  CAS  PubMed  Google Scholar 

  25. Lakhani SR (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer, Lyon

    Google Scholar 

  26. Oliveira TM, Elias J, Melo AF, Teixeira SR, Salomão Filho C, Gonçalves LM et al (2014) Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods. Insights Imaging 5(2):183–194

    Article  PubMed  PubMed Central  Google Scholar 

  27. Sinn H-P, Kreipe H (2013) A brief overview of the WHO classification of breast tumors. Breast Care 8(2):149–154

    Article  PubMed  PubMed Central  Google Scholar 

  28. Silverstein MJ (2003) The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186(4):337–343

    Article  PubMed  Google Scholar 

  29. Gilcrease M. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer: Hammond MEH, Hayes DF, Dowsett M, et al (Univ of Utah School of Medicine, Salt Lake City; Washington Univ School of Medicine, St Louis, MO; American Society of Clinical Oncology, Alexandria, VA; et al) Arch Pathol Lab Med 134: 907–922, 2010 §. Breast Dis Year Book Q 21(4):336–337

    Google Scholar 

  30. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013

    Article  PubMed  Google Scholar 

  31. Penault-Llorca F, Radosevic-Robin N (2017) Ki67 assessment in breast cancer: an update. Pathology 49(2):166–171

    Article  CAS  PubMed  Google Scholar 

  32. Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28(8):1700–1712

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Morigi C (2017) Highlights from the 15th St Gallen International Breast Cancer Conference 15–18 March, 2017, Vienna: tailored treatments for patients with early breast cancer. Ecancermedicalscience 11:732

    Article  PubMed  PubMed Central  Google Scholar 

  34. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98(19):10869–10874

    Article  PubMed  PubMed Central  Google Scholar 

  35. Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38(6):698–707

    Article  CAS  PubMed  Google Scholar 

  36. Eltahir Y, Werners LL, Dreise MM, van Emmichoven IAZ, Jansen L, Werker PM et al (2013) Quality-of-life outcomes between mastectomy alone and breast reconstruction: comparison of patient-reported BREAST-Q and other health-related quality-of-life measures. Plast Reconstr Surg 132(2):201e–209e

    Article  CAS  PubMed  Google Scholar 

  37. Schoenfeld JD, Harris JR (2011) Abbreviated course of radiotherapy (RT) for breast cancer. Breast 20:S116–SS27

    Article  PubMed  Google Scholar 

  38. Group EBCTC (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106

    Article  Google Scholar 

  39. Group EBCTC (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 378(9804):1707–1716

    Article  Google Scholar 

  40. Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J et al (2015) Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16(1):47–56

    Article  PubMed  Google Scholar 

  41. Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A et al (2017) Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial. JAMA Oncol 3(1):42–48

    Article  PubMed  Google Scholar 

  42. McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Elsevier. Lancet Oncol 383(9935):2127–2135

    Article  CAS  Google Scholar 

  43. Donker M, Slaets L, Rutgers E (2015) Axillary lymph node dissection versus axillary radiotherapy in patients with a positive sentinel node: the AMAROS trial. Ned Tijdschr Geneeskd 159:A9302-A

    Google Scholar 

  44. Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J et al (2006) Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 24(30):4888–4894

    Article  PubMed  Google Scholar 

  45. Blamey R, Pinder S, Ball G, Ellis I, Elston C, Mitchell M et al (2007) Reading the prognosis of the individual with breast cancer. Eur J Cancer 43(10):1545–1547

    Article  CAS  PubMed  Google Scholar 

  46. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980–991

    Article  CAS  PubMed  Google Scholar 

  47. Wishart G, Bajdik C, Azzato E, Dicks E, Greenberg D, Rashbass J et al (2011) A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol 37(5):411–417

    Article  CAS  PubMed  Google Scholar 

  48. Lumachi F, Luisetto G, MM Basso S, Basso U, Brunello A, Camozzi V (2011) Endocrine therapy of breast cancer. Curr Med Chem 18(4):513–522

    Article  CAS  PubMed  Google Scholar 

  49. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Pagani O, Regan MM, Walley B, Fleming GF, Colleoni M, Lang I, et al (2014) Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials. American Society of Clinical Oncology, Alexandria

    Google Scholar 

  51. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Moore HC, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372(10):923–932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J et al (2009) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509–518

    Article  CAS  PubMed  Google Scholar 

  54. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M (2009) Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? Target Oncol 4(2):77–88

    Article  PubMed  Google Scholar 

  55. Group EBCTC (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353–1361

    Article  CAS  Google Scholar 

  56. Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159

    Article  CAS  PubMed  Google Scholar 

  57. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K et al (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer. Cancer 106(10):2095–2103

    Article  CAS  PubMed  Google Scholar 

  58. Gianni L, Pienkowski T, Im Y-H, Tseng L-M, Liu M-C, Lluch A et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791–800

    Article  CAS  PubMed  Google Scholar 

  59. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios C et al (2017) 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28(1):16–33

    CAS  PubMed  Google Scholar 

  60. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638–3646

    Article  CAS  PubMed  Google Scholar 

  61. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936

    Article  CAS  PubMed  Google Scholar 

  62. Tripathy DSJ (2017) Ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III MONALEESA-7 trial. San Antonio breast cancer conference, abstract GS2-05

    Google Scholar 

  63. Piccart M, Hortobagyi GN, Campone M, Pritchard K, Lebrun F, Ito Y et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25(12):2357–2362

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Swain SM, Kim S-B, Cortés J, Ro J, Semiglazov V, Campone M et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533

    Article  CAS  PubMed  Google Scholar 

  66. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso M, Gilbert F et al (2016) Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 27(suppl_5):v103–vv10

    Article  CAS  PubMed  Google Scholar 

  67. Kornblum N, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella P et al (2017) Abstract S1-02: PrECOG 0102: a randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy. AACR. https://doi.org/10.1158/1538-7445.SABCS16-S1-02

  68. de la Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco F et al (2017) Breast Cancer immunology and immunotherapy: current status and future perspectives. Int Rev Cell Mol Biol 331:1–53

    Article  PubMed  Google Scholar 

  69. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R et al (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34(21):2460–2467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA et al (2013) Phase II trial of bicalutamide in patients with androgen receptor–positive, estrogen receptor–negative metastatic breast cancer. Clin Cancer Res 19(19):5505–5512

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J et al (2018) Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer. J Clin Oncol 36(9):884–890

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A et al (2016) A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol 27(5):812–818

    Article  CAS  PubMed  Google Scholar 

  73. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM et al (2013) Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31(17):2128–2135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Curigliano G, Cardinale D, Suter T, Plataniotis G, De Azambuja E, Sandri MT et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 23(suppl_7):vii155–vvii66

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland

    Inês Monteiro & Teresa Alvarez

  2. Department of Diagnostic and Interventional Radiology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland

    Jean-Yves Meuwly

  3. Breast Center, Medical Oncology, Department of Oncology, University Hospital CHUV, Lausanne, Switzerland

    Khalil Zaman

Authors
  1. Inês Monteiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teresa Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Yves Meuwly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Khalil Zaman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Medical Oncology, Federal University of São Paulo (UNIFESP) & Hospital Israelita Albert Einstein, São Paulo, Brazil, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal

    Ramon Andrade De Mello

  2. Oncology Department, Henry Dunant Hospital Center, Athens, Greece

    Giannis Mountzios

  3. Department of Biomedical Sciences and Medicine, Universidade do Algarve, Faro, Portugal

    Álvaro A. Tavares

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Monteiro, I., Alvarez, T., Meuwly, JY., Zaman, K. (2019). Breast Cancer. In: De Mello, R., Mountzios, G., Tavares, Á. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-16245-0_13

Download citation

Publish with us

Policies and ethics

Search

Navigation